Tyrosine kinase inhibitor STI-571: The new wonder drug of cancer therapy

Cancer Biology and Therapy

Volumn 3, Issue 4, 2004, Pages 393-394

  Haydon, Rex C ^a   Zhou, Lan ^a,b   He, Tong Chuan ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Chemotherapy; CML; Colon cancer; Gleevec; PTK inhibitor; Tyrosine kinase

Indexed keywords

BETA CATENIN; FLUOROURACIL; IMATINIB; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER RESISTANCE; CANCER THERAPY; CELL VIABILITY; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONCENTRATION RESPONSE; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; MOLECULAR WEIGHT; NOTE; PROTEIN EXPRESSION; SIDE EFFECT; UPREGULATION; CELL TRANSFORMATION; CHEMOPROPHYLAXIS; COLORECTAL TUMOR; DRUG ANTAGONISM; DRUG DESIGN; NEOPLASM;

ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; CHEMOPREVENTION; COLORECTAL NEOPLASMS; DRUG DESIGN; HUMANS; NEOPLASMS; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 16544365599     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.3.4.756     Document Type: Note

References (16)

1. Kolibaba KS, Druker BJ. Protein tyrosine kinases and cancer. Biochim Biophys Acta 1997; 1333:F217-48.
2. Shawver LK, Slamon D, Ullrich A. Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 2002; 1:117-23.
3. Becker J. Signal transduction inhibitors - a work in progress. Nat Biotechnol 2004; 22:15-8.
4. Kantarjian HM, Cortes JE, O'Brien S, Giles F, Garcia-Manero G, Faderl S, et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood 2003; 101:97-100.
5. Gardembas M, Rousselot P, Tulliez M, Vigier M, Buzyn A, Rigal-Huguet F, et al. Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase. Blood 2003; 102:4298-305.
6. Sureda A, Carrasco M, de Miguel M, Martinez JA, Conde E, Sanz MA, et al. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia. Haematologica 2003; 88:1213-20.
7. Dematteo R, Heinrich MC, El-Rifai WM, Demetri G. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 2002; 33:466-77.
8. Sjoblom T, Shimizu A, O'Brien KP, Pietras K, Dal Cin P, Buchdunger E, et al. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 2001; 61:5778-83.
9. Attoub S, Rivat C, Rodrigues S, Van Bocxlaer S, Bedin M, Bruyneel E, et al. The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy. Cancer Res 2002; 62:4879-83.
10. Soria JC, Johnson BE, Chevalier TL. Imatinib in small cell lung cancer. Lung Cancer 2003; 41:S49-53.
11. Farivar RS, Gardner-Thorpe J, Ito H, Arshad H, Zinner MJ, Ashley SW, et al. The efficacy of tyrosine kinase inhibitors on human pancreatic cancer cell lines. J Surg Res 2003; 115:219-25.
12. Zhou L, An N, Haydon RC, Zhou Q, Cheng H, Peng Y, et al. Tyrosine kinase inhibitor STI-571/Gleevec down-regulates the β-catenin signaling activity. Cancer Lett 2003; 193:161-70.
13. Azam M, Latek RR, Daley GQ. Mechanisms of auto inhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003; 112:831-43.
14. Barthe C, Cony-Makhoul P, Melo JV, Mahon JR. Roots of clinical resistance to STI-571 cancer therapy. Science 2001; 293:2163.
15. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293:876-80.
16. Hochhaus A, Kreil S, Corbin A, La Rosee P, Lahaye T, Berger U, et al. Roots of clinical resistance to STI-571 cancer therapy. Science 2001; 293:2163.